key: cord-0936188-9rctp6cz
authors: Ryan, Kathryn A.; Schewe, Katarzyna E.; Crowe, Jonathan; Fotheringham, Susan A.; Hall, Yper; Humphreys, Richard; Marriott, Anthony C.; Paterson, Jemma; Rayner, Emma; Salguero, Francisco J.; Watson, Robert J.; Whittaker, Catherine J.; Carroll, Miles W.; Dibben, Oliver
title: Sequential delivery of LAIV and SARS-CoV-2 in the ferret model can reduce SARS-CoV-2 shedding and does not result in enhanced lung pathology
date: 2021-02-01
journal: bioRxiv
DOI: 10.1101/2021.02.01.429110
sha: ddd5ee8510201d0372a3a98f925e9e2753cf4bff
doc_id: 936188
cord_uid: 9rctp6cz

Co-circulation of SARS-CoV-2 and influenza viruses could pose unpredictable risks to health systems globally, with recent studies suggesting more severe disease outcomes in co-infected patients. The lack of a readily available COVID-19 vaccine has reinforced the importance of influenza vaccine programmes during the COVID-19 pandemic. Live Attenuated Influenza Vaccine (LAIV) is an important tool in protecting against influenza, particularly in children. However, it is unknown whether LAIV administration might influence the outcomes of acute SARS-CoV-2 infection or disease. To investigate this, quadrivalent LAIV (QLAIV) was administered to ferrets 3 days pre- or post-SARS-CoV-2 infection. LAIV administration did not exacerbate SARS-CoV-2 disease course or lung pathology with either regimen. Additionally, LAIV administered prior to SARS-CoV-2 infection significantly reduced SARS-CoV-2 replication and shedding in the upper respiratory tract (URT). We conclude that LAIV administration in close proximity to SARS-CoV-2 infection does not exacerbate mild disease and can reduce SARS-CoV-2 shedding.

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in late 2019, resulting in a pandemic and rapidly increasing the burden of respiratory illness globally. As of January 2021 the WHO reported over 98 million confirmed COVID-19 cases with more than 2 million deaths worldwide 1 . The prospect of SARS-CoV-2 co-circulation with other respiratory viruses, particularly influenza, has raised major concerns over potential stresses to healthcare systems. A number of seasonal respiratory viruses including influenza A virus, influenza B virus and SARS-CoV-2 have been found in co-infected patients [2] [3] [4] [5] [6] . SARS-CoV-2 and influenza viruses are easily transmissible within the population and the severity of disease caused in each case can range from asymptomatic to severe with a fatal outcome 7,8 . However, the prevalence of COVID-19 and influenza coinfections rates varies across the literature 9,10 and the implications for disease

To assess the implications of LAIV and SARS-CoV-2 co-infection and its impact on COVID-19 disease severity, SARS-CoV-2 at 6.7 log10 PFU per dose and quadrivalent LAIV (QLAIV) at 4.0 log10 FFU per dose, per strain were administered intranasally to groups of six ferrets (Figure 1a) . Optimization of these SARS-CoV-2 and QLAIV doses was described by Ryan et al. 35 and LAIV only (LAIV/Mock) were also included. All study groups are summarized in Figure 1c . The endpoints of the study were the histopathological examination of lung and nasal cavity tissues and the quantification of SARS-CoV-2 virus RNA in throat swabs, nasal cavity tissues and lung tissues.

Histopathological examination shows no effect of LAIV on SARS-CoV-2 lung pathogenesis and only a mild increase in the nasal cavity. All ferrets were euthanized 6 days after SARS-CoV-2 challenge. Pathological changes were assessed in all lung lobes and the nasal cavity.

In the nasal cavity tissues, inflammatory and degenerative changes were observed in the mucosa which were similar in appearance for all animals in all groups ( Figure 2 ). These comprised mixed inflammatory cells, mainly lymphocytes, infiltrating the propria-submucosa and neutrophils infiltrating the epithelial layer, with variable presence and severity of epithelial degeneration, loss and areas of denudation. Lesions were present in both the rostral and caudal areas of the nasal cavity, containing both the respiratory and olfactory epithelia, without a detectable predilection for a specific location. Patchy exudates, comprising degenerate neutrophils, epithelial cells and mucus, were also noted. 

In order to investigate the effect of LAIV on SARS-CoV-2 replication and pathology we applied the ferret model for mild SARS-CoV-2 clinical disease described by Ryan et al. 35 . In SARS-CoV-2 infected control animals, mild histopathological changes were observed in respiratory tract tissues, corresponding to the mild disease pattern described previously 35 . For all animals in the SARS-CoV-2 only group (Mock/SARS-CoV-2), microscopic lesions were present with greatest prominence in the nasal cavity tissue and comprised of acute to sub-acute, inflammatory and degenerative changes. Histopathological changes were also seen in the lungs, but with a lower frequency and severity.

These findings agreed with previous challenge study data and reflected a reduced severity of pathological changes in the lower respiratory tract (LRT) compared to the URT 35 . Additionally, the mild disease phenotype observed in ferrets appeared to model the mild COVID-19 progression in children [30] [31] [32] .

Mild histopathological changes in both the lungs and nasal turbinates were also noted in animals that received LAIV only (LAIV/Mock). LAIV has an excellent safety profile in clinical studies 19, 29 , suggesting that this level of pathology resulted from LAIV induced immune response. This was likely due to the higher pathogenicity of wild type influenza virus relative to LAIV, in concert with a more severe COVID-19 disease model in mice.

We hypothesize that viral competition might play a role in the interaction of LAIV and SARS-CoV-2, as well as LAIV-mediated non-specific immune response.

Previously, LAIV has been shown to provide non-specific immediate protection against Respiratory Syncytial Virus infection in mice 38 . In another mouse model copies/ml, were assigned the value of 5 copies/µl, this equates to 3.81 log10 copies/ml, whilst undetected samples were assigned the value of < 2.3 copies/µl, equivalent to the assay's lower limit of detection (LoD) which equates to 3.47 log10 copies/ml. Positive tissue samples detected below the limit of quantification (LoQ) of 4.76 log10 copies/ml were assigned the value of 5 copies/µl, this equates to 4.46 log10 copies/g, whilst undetected samples were assigned the value of < 2.3 copies/µl, equivalent to the assay's lower limit of detection (LoD) which equates to 4.76 log10 copies/g.

Page 15 of 29

Virus replication in tissues was measured by RT-qPCR at day 6 post-challenge only. Nasal cavity tissue RT-qPCR copy numbers were expressed as log10

values. For throat swab PCR data, the geometric mean of PCR copy numbers for days 1 to 6 post-challenge was taken for each animal and expressed as a log10

value, generating a single value measuring shedding over time for each animal.

Both data sets were then tested using a one-way ANOVA followed by a comparison of study group means using the Tukey Honest Significant Difference test. All statistical analysis was carried out in JMP v14.3 (SAS Institute Inc.).

Statistical significance are shown on figures by horizontal lines and P-value indicators: *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. Columns and error bars for all virus titer data show group geometric mean and interquartile range.

To enable visualization of histopathology parameters from individual animals across the various study endpoints, all data were expressed as heatmaps. The throat swabs were taken at days 1, 2, 3, 4, 5 and 6 pc and SARS-CoV-2 viral loads were determined by RT-qPCR. The symbols show the geometric mean of virus titres over 6 days for one ferret, bars represent the group mean of 6 ferret with standard deviation. Statistical significance are shown by horizontal lines and P-value indicators: ns P > 0.05, **P < 0.01, ****P < 0.0001. Horizontal dotted lines show the lower limit of quantification (LoQ=4.11 log10 RNA copies/ml/day) and the lower limit of detection (LoD=3.47 log10 RNA copies/ml/day). SARS-CoV-2 shedding in group Mock/SARS-CoV-2 was significantly higher than in group LAIV/SARS-CoV-2 (p=0.0059) and in group LAIV/Mock (p<0.0001). No significant changes were noted between group SARS-CoV-2/LAIV and control group Mock/SARS-CoV-2 (p=0.51). (b) The SARS-CoV-2 RNA was measured in nasal cavity tissue homogenates by RT-qPCR. The symbols show the virus titre measured in nasal cavity tissue at day 6 for one ferret, bars represent the group mean of 6 ferret with standard deviation. Statistical significance is shown by horizontal lines and P-value indicators: ns P > 0.05, **P < 0.01. Horizontal dotted lines show the lower limit of quantification (LoQ=4.76 log10 RNA copies/g) and the lower limit of detection (LoD=4.12 log10 RNA copies/g). SARS-CoV-2 shedding in group Mock/SARS-CoV-2 was significantly higher than in group LAIV/Mock (p=0.0015). No statistical differences between SARS-CoV-2 only control group (Mock/SARS-CoV-2) and both coinfected groups LAIV/SARS-CoV-2 and SARS-CoV-2/LAIV were noted in nasal cavity tissue (p=0.2924 and p=0.7552, respectively).

WHO, Coronavirus Disease (COVID-19) Dashboard. WHO

Are coinfections with COVID-19 and influenza low or underreported? An observational study examining current published literature including three new unpublished cases

Multiple versus single virus respiratory infections: viral load and clinical disease severity in hospitalized children. Influenza and other respiratory viruses

Coinfection and Other Clinical Characteristics of COVID-19 in Children. Pediatrics

A case series of coinfection with SARS-CoV-2 and influenza virus in

Respiratory medicine case reports

The epidemiology and clinical characteristics of coinfection of SARS-CoV-2 and influenza viruses in patients during COVID-19 outbreak

Interactions between SARS-CoV-2 and Influenza and the impact of coinfection on disease severity: A test negative design

Sequential infection with influenza A virus followed by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) leads to more severe disease and encephalitis in a mouse model of COVID-19

Food and Drug Administration (FDA)

Healthcare products Regulatory Agency. Medicines & Healthcare products Regulatory Agency

Medicines and Healthcare products Regulatory Agency (MHRA)

Medicines and Healthcare products Regulatory Agency

Development and persistence of local and systemic antibody responses in adults given live attenuated or inactivated influenza A virus vaccine

Immune responses after live attenuated influenza vaccination. Human vaccines & immunotherapeutics

Live attenuated versus inactivated influenza vaccine in infants and young children. The New England journal of medicine

Safety of live attenuated influenza vaccine (LAIV) in children with moderate to severe asthma

End of season influenza vaccine effectiveness in primary care in adults and children in the United Kingdom

Effectiveness of Live Attenuated vs Inactivated Influenza Vaccines in Children During the

A Canadian Immunization Research Network (CIRN) Study. JAMA pediatrics

A pilot study of the effectiveness of a school-based influenza vaccination program. Pediatrics

Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology

Asthma exacerbations among asthmatic children receiving live attenuated versus inactivated influenza vaccines. Vaccine

Evaluation of the safety of live attenuated influenza vaccine (LAIV) in children and adolescents with asthma and high-risk conditions: a population-based prospective cohort study conducted in England with the Clinical Practice Research Datalink

Children and SARS-CoV-2 infection: innocent bystanders…until proven otherwise. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases

Prevalence of SARS-CoV-2 Infection in Children Without Symptoms of Coronavirus Disease

Clinical Presentation, Infectivity, and Immune Responses

Infection and Rapid Transmission of SARS-CoV-2 in Ferrets. Cell host & microbe

Susceptibility of ferrets, cats, dogs, and other domesticated animals to SARS-coronavirus 2

Dose-dependent response to infection with SARS-CoV-2 in the ferret model and evidence of protective immunity

Defining the root cause of reduced H1N1 live attenuated influenza vaccine effectiveness: low viral fitness leads to inter-strain competition

Transmissibility of COVID-19 depends on the viral load around onset in adult and symptomatic patients. PloS one

Non-specific Effect of Vaccines: Immediate Protection against Respiratory Syncytial Virus Infection by a Live Attenuated Influenza Vaccine. Frontiers in microbiology

Immediate and broad-spectrum protection against heterologous and heterotypic lethal challenge in mice by live influenza vaccine. Vaccine

Trivalent live attenuated intranasal influenza vaccine administered during the 2003-2004 influenza type A (H3N2) outbreak provided immediate, direct, and indirect protection in children. Pediatrics

A whole genome transcriptional analysis of the early immune response induced by live attenuated and inactivated influenza vaccines in young children. Vaccine

Could an Unrelated Live Attenuated Vaccine Serve as a Preventive Measure To Dampen Septic Inflammation Associated with COVID-19 Infection?. mBio

Can existing live vaccines prevent COVID-19?

Isolation and rapid sharing of the 2019 novel coronavirus (SARS-CoV-2) from the first patient diagnosed with COVID-19 in Australia. The Medical journal of Australia

Metagenomic Nanopore Sequencing of Influenza Virus Direct from Clinical Respiratory Samples

Multiple amino acid residues confer temperature sensitivity to human influenza virus vaccine strains (FluMist) derived from cold-adapted A/Ann Arbor/6/60. Virology

Multiple gene segments control the temperature sensitivity and attenuation phenotypes of ca B/Ann Arbor/1/66

Surface glycoproteins of influenza A H3N2 virus modulate virus replication in the respiratory tract of ferrets

Replication of live attenuated influenza vaccine viruses in human nasal epithelial cells is associated with H1N1 vaccine effectiveness. Vaccine

We thank Sarah Woods for FFA titration of vaccine formulation. We thank Laura